An ADA workgroup [26] and an ADA consensus conference on diabetic kidney disease [27] have suggested that clinicians should exercise precaution when selecting and dosing SU and insulin for patients with diabetes and CKD. The gene discussed is INS; the disease is diabetes mellitus.